Hangzhou TianMuShan Pharmaceutical Enterprise Co (600671) Fair Value & Analysis
Healthcare · CN · Market cap 2.6B CNY
Fair value as of: Aug 9, 2026
From 16 valuation models · updated yesterday
Share price +13.0% over the past month.
Below-average quality, and screening another 89% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥3.08). The favourable scenario is already priced in.
- Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 9, 2026.
How to read this chart
60‑month range ¥5.85 – ¥22.50 · fair‑value band ¥1.80 – ¥3.08 · the ¥21.70 price screens above the ¥2.46 fair value. Dashed = 300-day average. As of Aug 9, 2026.
Analysis
Hangzhou TianMuShan Pharmaceutical Enterprise Co (600671) currently trades at ¥21.70, while our model-based Fair Value estimate is ¥2.46, implying the stock looks roughly 88.7% overvalued today. The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Hangzhou TianMuShan Pharmaceutical Enterprise Co generated revenue of 204M CNY at a net margin of 8.0%. Revenue declined 15.1% year over year. It earns a return on equity of 8.0%. Net debt stands at 112M CNY. Fundamentals as of Aug 9, 2026
Our scenario range runs from ¥1.80 (bear case) to ¥3.08 (bull case); at ¥21.70, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 7% below its 52-week high and 74% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -25% fair-value upside, at -89%, 600671 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 16 models by family
Widest divergence: Growth Earnings (¥2.57) versus Asset-Based (¥0.3900). Highest evidence: Residual Income (76).
Notify me when 600671 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 40 · Market factors (momentum, volatility) 69
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution businesses in China.
Full company description
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution businesses in China. The company produces tablets, granules, pills, oral solutions, and other medications; and health food products, including oral liquids, syrups, eye drops, pills, soft capsules, tablets, and granules. It also sells prepared slices of traditional Chinese medicine. In addition, the company operates Chinese medicine clinic; provision of traditional chinese medicine clinic, software development, remote health management, commercial complex management, and internet information services; food business; and sale of health food products. The company was founded in 1958 and is headquartered in Hangzhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Hangzhou TianMuShan Pharmaceutical Enterprise Co reported revenue of ¥212M in FY2025 versus ¥147M in FY2021, a compound +9.5%/yr. Reported net income was ¥17.6M in FY2025.
600671 screens 89% overvalued. Compare with Eli Lilly and Company →
Peer Group
Drug Manufacturers - General · 76 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Aug 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,182 | $396.77 | -66% |
| Johnson & Johnson, JNJ | $257.59 | $169.04 | -34% |
| AbbVie Inc ABBV | $254.49 | $67.72 | -73% |
| Roche Holding 1RO | €392.80 | €226.68 | -42% |
| Merck & Co MRK | €108.08 | €121.54 | +12% |
| Novartis AG NVSN | 2,742 MXN | 2,379 MXN | -13% |
| AstraZeneca PLC AZN | $171.61 | $129.54 | -25% |
| Novo Nordisk A/S NOVOB | kr 329.90 | kr 409.46 | +24% |
| Amgen Inc AMGN | $363.39 | $252.02 | -31% |
| Sanofi SNYN | 770.00 MXN | 1,251 MXN | +63% |
Compare Hangzhou TianMuShan Pharmaceutical Enterprise Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Hangzhou TianMuShan Pharmaceutical Enterprise Co (600671) overvalued or undervalued?
What is the fair value of 600671?
What is the quality score of 600671?
What is the revenue of Hangzhou TianMuShan Pharmaceutical Enterprise Co (600671)?
What is the net profit margin of 600671?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Hangzhou TianMuShan Pharmaceutical Enterprise Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.